Anvisa Approves Second Generic of Semaglutide in Brazil

Globo

Lean Right

Factuality

Ownership

g1 in 1 Minute: Anvisa approves the first generic semaglutide pen of the country The National Agency for Health Surveillance (Anvisa) approved the registration of the second generic semaglutide medicine in Brazil. The authorisation was granted to Germed Pharmaceutical and published on Monday (24). Semmaglutide is the active principle behind medicines such as Ozempic and Wegovy, from Novo Nordisk, used in the treatment of type 2 diabetes and obes…

Correio Braziliense

Factuality

Ownership

Manufactured by Germed, new medicine will cost at least 35% unless the reference and strengthens generic market

A TARDE

Factuality

Ownership

The registration of the second generic medicine based on semaglutide was approved by the National Agency for Health Surveillance (Anvisa) in Brazil. The decision was published in the Official Journal of the Union (DOU) on Monday, 24.The product, produced by Germed Pharmaceutical, is indicated for the treatment of type 2 diabetes and belongs to the class of GLP-1 receptor agonists, the same as medicines such as Ozempic and Wegovy.The medicine wil…

CNN Brasil

Factuality

Ownership

Decision published in the Official Journal of the Union on Monday (24)

Metrópoles

Factuality

Ownership

New registration increases competition and can reduce prices, since generics cost at least 35% less than the original